Emergent BioSolutions sells Baltimore-Bayview manufacturing site to Syngene for $36.5M

Emergent BioSolutions Inc.

Sale of Bayview drug substance manufacturing facility to Syngene Intl for ~$36.5M; closing expected Q1 2025.
Emergent retains rights to secure manufacturing services and capacity at the facility for growth and pandemic response.
Emergent continues streamlined manufacturing network with facilities in Lansing, MI and Winnipeg, MB.
Bayview site received FDA 'No Action Indicated' (NAI) inspection outcome in March 2024.
CEO Joe Papa states sale advances multi-year transformation plan and turnaround phase.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.